• Are US flu death figures more PR than science?

      Doshi, Peter (BMJ Publishing Group, 2005-12-10)
    • Influenza vaccination: policy versus evidence

      Doshi, Peter (BMJ Publishing Group, 2006-11)
    • Preventing flu-like illness: Reason for optimism

      Doshi, Peter (BMJ Publishing Group, 2008-01-24)
    • Trends in recorded influenza mortality: United States, 1900-2004

      Doshi, Peter (American Public Health Association, 2008-05)
      OBJECTIVES: I sought to describe trends in historical influenza mortality data in the United States since 1900 and compare pandemic with nonpandemic influenza seasons. -- METHODS: I compiled a database of monthly influenza-classed death rates from official US mortality tables for the years 1900 to 2004 (1905-1909 excluded), from which I calculated adjusted influenza season (July 1-June 30) mortality rates. -- RESULTS: An overall and substantial decline in influenza-classed mortality was observed during the 20th century, from an average seasonal rate of 10.2 deaths per 100 000 population in the 1940s to 0.44 per 100 000 by the 1990s [corrected] . The 1918-1919 pandemic stands out as an exceptional outlier. The 1957-1958 and 1968-1969 influenza pandemic seasons, by contrast, displayed substantial overlap in both degree of mortality and timing compared with nonpandemic seasons. -- CONCLUSIONS: The considerable similarity in mortality seen in pandemic and non-pandemic influenza seasons challenges common beliefs about the severity of pandemic influenza. The historical decline in influenza-classed mortality rates suggests that public health and ecological factors may play a role in influenza mortality risk. Nevertheless, the actual number of influenza-attributable deaths remains in doubt.
    • The elusive definition of pandemic influenza

      Doshi, Peter (World Health Organization, 2008-07-01)
      There has been considerable controversy over the past year, particularly in Europe, over whether the World Health Organization (WHO) changed its definition of pandemic influenza in 2009, after novel H1N1 influenza was identified. Some have argued that not only was the definition changed, but that it was done to pave the way for declaring a pandemic. Others claim that the definition was never changed and that this allegation is completely unfounded. Such polarized views have hampered our ability to draw important conclusions. This impasse, combined with concerns over potential conflicts of interest and doubts about the proportionality of the response to the H1N1 influenza outbreak, has undermined the public trust in health officials and our collective capacity to effectively respond to future disease threats. WHO did not change its definition of pandemic influenza for the simple reason that it has never formally defined pandemic influenza. While WHO has put forth many descriptions of pandemic influenza, it has never established a formal definition and the criteria for declaring a pandemic caused by the H1N1 virus derived from "pandemic phase" definitions, not from a definition of "pandemic influenza". The fact that despite ten years of pandemic preparedness activities no formal definition of pandemic influenza has been formulated reveals important underlying assumptions about the nature of this infectious disease. In particular, the limitations of "virus-centric" approaches merit further attention and should inform ongoing efforts to "learn lessons" that will guide the response to future outbreaks of novel infectious diseases.
    • Popular and scientific attitudes regarding pandemic influenza

      Doshi, Peter (Centers for Disease Control and Prevention (CDC), 2008-09-14)
    • Calibrated response to emerging infections

      Doshi, Peter (BMJ Publishing Group, 2009-09-03)
    • Neuraminidase inhibitors--the story behind the Cochrane review

      Doshi, Peter (BMJ Publishing Group, 2009-12-08)
    • Another question for GSK

      Doshi, Peter; Jefferson, Tom (BMJ Publishing Group, 2010-06-29)
    • Ensuring safe and effective drugs: who can do what it takes?

      Jefferson, Tom; Doshi, Peter; Thompson, Matthew J.; Heneghan, Carl (BMJ Publishing Group, 2011-01-11)
    • Does oseltamivir really reduce complications of influenza?

      Cochrane Neuraminidase Inhibitors Review Team; Del Mar, Chris; Doshi, Peter; Hama, Rokuro, M.D.; Heneghan, Carl; Jefferson, Tom; Jones, Mark A., B.Sc., Ph.D.; Thompson, Matthew J. (University of Chicago Press, 2011-12-15)
    • Rethinking credible evidence synthesis

      Doshi, Peter; Jones, Mark A., B.Sc., Ph.D.; Jefferson, Tom (BMJ Publishing Group, 2012-01-17)
    • The imperative to share clinical study reports: recommendations from the Tamiflu experience

      Doshi, Peter; Jefferson, Tom; Del Mar, Chris (Public Library of Science, 2012-04-10)
      Summary points: - Systematic reviews of published randomized clinical trials (RCTs) are considered the gold standard source of synthesized evidence for interventions, but their conclusions are vulnerable to distortion when trial sponsors have strong interests that might benefit from suppressing or promoting selected data. - More reliable evidence synthesis would result from systematic reviewing of clinical study reports—standardized documents representing the most complete record of the planning, execution, and results of clinical trials, which are submitted by industry to government drug regulators. - Unfortunately, industry and regulators have historically treated clinical study reports as confidential documents, impeding additional scrutiny by independent researchers. - We propose clinical study reports become available to such scrutiny, and describe one manufacturer's unconvincing reasons for refusing to provide us access to full clinical study reports. We challenge industry to either provide open access to clinical study reports or publically defend their current position of RCT data secrecy.
    • Influenza vaccination of health care workers

      Doshi, Peter; Abi-Jaoude, Elia; Lexchin, Joel; Jefferson, Tom; Thomas, Roger E., M.D., Ph.D. (Canadian Medical Association, 2013-02-05)
    • Influenza: marketing vaccine by marketing disease

      Doshi, Peter (BMJ Publishing Group, 2013-05-16)
    • Restoring invisible and abandoned trials: a call for people to publish the findings

      Doshi, Peter; Dickersin, Kay; Healy, David, 1954-; Vedula, S. Swaroop; Jefferson, Tom (BMJ Publishing Group, 2013-06-13)
    • YODA and truth seeking in medicine

      Doshi, Peter; Vedula, S. Swaroop; Li, Tianjing, Ph.D. (BMJ Publishing Group, 2013-07-02)
    • Putting GlaxoSmithKline to the test over paroxetine

      Doshi, Peter (BMJ Publishing Group, 2013-11-12)